Biotechs, generic-drug makers and ethical-drug makers are some of the highest-ranked industry groups among the 197 that IBD tracks, and with recent view-topping earnings reports, FDA approvals and strategic divestments, they’re proving their strength. Five hot drug stocks lead IBD’s Screen Of The Day, Big Cap Leaders: Gilead Sciences (GILD), Jazz Pharmaceuticals (JAZZ), Allergan (AGN), Regeneron Pharmaceuticals (REGN) and Mallinckrodt (MNK).
If at first you don’t succeed, try, try again. Today’s Young Guns Screen of the Day, which groups top-rated stocks that went public less than 15 years ago, features one particular pharmaceutical stock that is nearing a second breakout. Jazz Pharmaceuticals (JAZZ), which made its stock market debut eight years ago, is in an area of consolidation and attempting a re-breakout following a failed breakout from a cup-with-handle base. Shares retreated
Jazz Pharmaceuticals shares fell late Tuesday after the drugmaker topped fourth-quarter estimates but guided 2015 revenue and profit below views. That followed United Therapeutics (UTHR), which also logged better-than-expected Q4 results. Jazz (JAZZ) earned $2.44 a share excluding a variety of items, up 42% a year earlier and 14 cents above consensus estimates. Revenue gained 39% to $328.1 million vs. views for $319.1 million.